Quinolone-induced psychosis: an updated review

Authors

  • Raul F. Palma-Alvarez Servicio de Psiquiatría, Hospital Universitari Vall d’Hebron. Barcelona. España; Grupo de Psiquiatría, Salud Mental y Adicciones, Vall d’Hebron Research Institute (VHIR). Barcelona. España; Biomedical Network Research Centre on Mental Health (CIBERSAM). Barcelona. España; Departamento de Psiquiatría y Medicina Legal, Universitat Autònoma de Barcelona. Barcelona. España
  • Juan Duque-Yemail Servicio de Psiquiatría, Hospital Universitari Vall d’Hebron. Barcelona. España
  • Elena Ros-Cucurull Servicio de Psiquiatría, Hospital Universitari Vall d’Hebron. Barcelona. España; Grupo de Psiquiatría, Salud Mental y Adicciones, Vall d’Hebron Research Institute (VHIR). Barcelona. España; Biomedical Network Research Centre on Mental Health (CIBERSAM). Barcelona. España; Departamento de Psiquiatría y Medicina Legal, Universitat Autònoma de Barcelona. Barcelona. España
  • María Robles-Martínez Instituto de Neuropsiquiatría y Adicciones (INAD). Parc de Salut Mar, Barcelona. España. Hospital del Mar. Barcelona. España; Institut Hospital del Mar d´Investigacions Biomèdiques (IMIM), Barcelona. España
  • Marta Perea-Ortueta Servicio de Psiquiatría, Hospital Universitari Vall d’Hebron. Barcelona. España; Grupo de Psiquiatría, Salud Mental y Adicciones, Vall d’Hebron Research Institute (VHIR). Barcelona. España; Biomedical Network Research Centre on Mental Health (CIBERSAM). Barcelona. España; Departamento de Psiquiatría y Medicina Legal, Universitat Autònoma de Barcelona. Barcelona. España
  • Lara Grau-López Servicio de Psiquiatría, Hospital Universitari Vall d’Hebron. Barcelona. España; Grupo de Psiquiatría, Salud Mental y Adicciones, Vall d’Hebron Research Institute (VHIR). Barcelona. España; Biomedical Network Research Centre on Mental Health (CIBERSAM). Barcelona. España; Departamento de Psiquiatría y Medicina Legal, Universitat Autònoma de Barcelona. Barcelona. España
  • Josep A. Ramos-Quiroga Servicio de Psiquiatría, Hospital Universitari Vall d’Hebron. Barcelona. España; Grupo de Psiquiatría, Salud Mental y Adicciones, Vall d’Hebron Research Institute (VHIR). Barcelona. España; Biomedical Network Research Centre on Mental Health (CIBERSAM). Barcelona. España; Departamento de Psiquiatría y Medicina Legal, Universitat Autònoma de Barcelona. Barcelona. España

Keywords:

Quinolones, Psychosis, Ciprofloxacin, Levofloxacinn, Psychotic Induced Disorder

Abstract

Quinolones are an antibiotic group widely used due to their antimicrobial action and security profile, however, it has been described neuropsychiatric adverse effects, being induced-psychotic episodes one of the most clinically relevant. Nevertheless, this secondary effect has been scarcely studied. A literature search using PRISMA guidelines was performed between 01/01/1962 and 01/31/2019 on PubMed and ScienceDirect, including manuscripts which described substance-induced psychotic disorder according to DSM-5 and in which the symptomatology was not attributable to an acute confusional state (delirium) or to other induced psychiatric disorders. 459 articles were found, but only 27 manuscripts fulfilled inclusion criteria (n=27 patients, median age of 36.15±16.96 years). Ciprofloxacin, levofloxacin and ofloxacin were the main antibiotics implicated. Quinolone-induced psychosis is a clinical relevant issue due to the high prescription of these antibiotics and the severity of this clinical syndrome. In general, this syndrome can remit in a few days with the withdrawal of the quinolone and performing symptomatic support if it is necessary. Finally, it is important to perform further research on this issue.

Published

2020-05-01

How to Cite

Palma-Alvarez, Raul F., et al. “Quinolone-Induced Psychosis: An Updated Review”. Actas Españolas De Psiquiatría, vol. 48, no. 3, May 2020, pp. 126-37, https://actaspsiquiatria.es/index.php/actas/article/view/279.

Issue

Section

Review